fluorouracil has been researched along with Benign Supratentorial Neoplasms in 2 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was a randomized, multicenter Phase II trial comparing the effect of perioperative implantation of 5-fluorouracil-releasing microspheres followed by early radiotherapy (Arm A) and early radiotherapy alone (Arm B) in patients with gross total resection of high-grade glioma." | 9.11 | Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. ( Assaker, R; Bataille, B; Bauchet, L; Benoit, JP; Capelle, L; Dorwling-Carter, D; Faisant, N; François, P; Fuentes, S; Guyotat, J; Menei, P; Paquis, P; Parker, F; Sabatier, J, 2005) |
| "This Phase III trial tested the efficacy and safety of intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of newly resected malignant glioma, comparing intra-arterial BCNU and intravenous BCNU (200 mg/sq m every 8 weeks), each regimen without or with intravenous 5-fluorouracil (1 gm/sq m three times daily given 2 weeks after BCNU)." | 9.07 | A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohff, J; Robertson, JT; Selker, RG; Shapiro, WR; VanGilder, JC, 1992) |
| "This study was a randomized, multicenter Phase II trial comparing the effect of perioperative implantation of 5-fluorouracil-releasing microspheres followed by early radiotherapy (Arm A) and early radiotherapy alone (Arm B) in patients with gross total resection of high-grade glioma." | 5.11 | Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. ( Assaker, R; Bataille, B; Bauchet, L; Benoit, JP; Capelle, L; Dorwling-Carter, D; Faisant, N; François, P; Fuentes, S; Guyotat, J; Menei, P; Paquis, P; Parker, F; Sabatier, J, 2005) |
| "This Phase III trial tested the efficacy and safety of intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of newly resected malignant glioma, comparing intra-arterial BCNU and intravenous BCNU (200 mg/sq m every 8 weeks), each regimen without or with intravenous 5-fluorouracil (1 gm/sq m three times daily given 2 weeks after BCNU)." | 5.07 | A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohff, J; Robertson, JT; Selker, RG; Shapiro, WR; VanGilder, JC, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Menei, P | 1 |
| Capelle, L | 1 |
| Guyotat, J | 1 |
| Fuentes, S | 1 |
| Assaker, R | 1 |
| Bataille, B | 1 |
| François, P | 1 |
| Dorwling-Carter, D | 1 |
| Paquis, P | 1 |
| Bauchet, L | 1 |
| Parker, F | 1 |
| Sabatier, J | 1 |
| Faisant, N | 1 |
| Benoit, JP | 1 |
| Shapiro, WR | 1 |
| Green, SB | 1 |
| Burger, PC | 1 |
| Selker, RG | 1 |
| VanGilder, JC | 1 |
| Robertson, JT | 1 |
| Mealey, J | 1 |
| Ransohff, J | 1 |
| Mahaley, MS | 1 |
2 trials available for fluorouracil and Benign Supratentorial Neoplasms
| Article | Year |
|---|---|
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial.
Topics: Antimetabolites, Antineoplastic; Biodegradation, Environmental; Combined Modality Therapy; Delayed-A | 2005 |
A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1992 |